<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191424</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1017-PR-0034</org_study_id>
    <secondary_id>2010-018947-33</secondary_id>
    <nct_id>NCT01191424</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.</brief_title>
  <acronym>ADONE</acronym>
  <official_title>A Multicenter, Multinational, Single-Dose, Open Label, Randomized, 2-Way Crossover, Clinical Pharmacology Study of CHF 1535 100/6 Next™ DPI (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg) Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescents and Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the CHF 1535 (fixed combination of
      Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg) delivered via the
      NEXT Dry Powder Inhaler (DPI) does not show a greater exposure to BDP,
      Beclometasone-17-Monopropionate(B17MP, active metabolite of BDP) and FF in comparison to a
      free combination of BDP DPI plus FF DPI licensed products after a morning dose administration
      of BDP and FF (total dose of BDP 400 µg / FF 24 µg) in adolescent and adult asthmatic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic exposure to B17MP (active metabolite of BDP) after single dose (4 inhalations) of CHF1535 100/6 NEXT DPI in comparison with an already approved free combination of BDP DPI and FF DPI</measure>
    <time_frame>0-8hrs</time_frame>
    <description>Plasma AUC0-t for B17MP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Different pharmacokinetic parameters</measure>
    <time_frame>0-8hrs</time_frame>
    <description>BDP/B17MP and FF PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function parameters</measure>
    <time_frame>0-8hrs</time_frame>
    <description>Peak FEV1, FEV1 time averaged value (FEV1 AUC0-t/8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>0-8hrs</time_frame>
    <description>Plasma Potassium Cmin, tmin and AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>0-8hrs</time_frame>
    <description>Plasma Glucose Cmax, tmax, AUC0-2h and AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>0-8hrs</time_frame>
    <description>time averaged value (AUC0-t/8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>during the whole study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF1535 NEXT DPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free combination BDP and FF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 NEXT DPI</intervention_name>
    <description>FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER</description>
    <arm_group_label>CHF1535 NEXT DPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP DPI and formoterol DPI</intervention_name>
    <description>FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI</description>
    <arm_group_label>Free combination BDP and FF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Male and female adolescents (≥ 12 years old) and adults (≥18 and ≤ 65 years old)

          2. Written informed consent;

          3. Diagnosis of asthma as defined in the GINA guidelines;

          4. Patients with stable asthma, according to the Investigator's opinion;

          5. Asthmatic patients already treated with ICS or using short-acting inhaled β2-agonists
             as reliever to control asthma symptoms;

          6. Patients with a forced expiratory volume in one second (FEV1) &gt; 70% of predicted
             values;

          7. Patients with a peak inspiratory flow (PIF) &gt; 40 L/min

          8. Reversibility test;

          9. Non- or ex-smokers;

         10. A cooperative attitude and ability to be trained about the proper use of DPI and
             compliant to study procedures;

        Main Exclusion Criteria:

          1. Pregnant or lactating female;

          2. Having received an investigational drug within 2 months before the screening visit

          3. Diagnosis of COPD as defined by the current GOLD guidelines;

          4. Significant medical history of and/or treatments for cardiac, renal, neurological,
             hepatic, endocrine diseases, or any laboratory abnormality;

          5. Known hypersensitivity to the active treatments;

          6. History of drug addiction or excessive use of alcohol;

          7. Treatment with a xanthine derivative (e.g. theophylline) formulation in the 4 weeks
             prior to screening;

          8. Hospitalization due to asthma exacerbation or asthma exacerbation within 1 month prior
             to the screening visit;

          9. Inability to perform the required breathing technique and blood sampling;

         10. Lower respiratory tract infection within 1 month prior to the screening visit;

         11. Blood donation (450 mL or more) or significant blood loss in the 12 weeks before the
             screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medicines Evaluation Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Bisgaard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Copenhagen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018947-33</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>PK</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

